Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the broad classification of eczema. It is the most common skin disease in children, with 50% of patients experiencing onset of disease within their 1st year of life and 85% before the age of 5.
For questions, please contact Liis Shea, Program Director, at firstname.lastname@example.org.
Interventions of Interest:
- abrocitinib (Pfizer)
- tralokinumab (LEO Pharma)
- baricitinib (Olumiant®, Eli Lilly, Incyte Corporation)
- upadacitinib (Rinvoq®, AbbVie)
- ruxolitinib (Incyte Corporation)
View the Key Stakeholder List.